Erysipeloid rash: A rare adverse event induced by gemcitabine.
Identifieur interne : 000999 ( PubMed/Corpus ); précédent : 000998; suivant : 000A00Erysipeloid rash: A rare adverse event induced by gemcitabine.
Auteurs : Ana Ruiz-Casado ; David Gutiérrez ; Ignacio JuezSource :
- Journal of cancer research and therapeutics [ 1998-4138 ]
English descriptors
- KwdEn :
- Adenocarcinoma (drug therapy), Adenocarcinoma (pathology), Adult, Deoxycytidine (adverse effects), Deoxycytidine (analogs & derivatives), Erysipeloid (chemically induced), Erysipeloid (pathology), Exanthema (chemically induced), Exanthema (pathology), Female, Humans, Pancreatic Neoplasms (drug therapy), Pancreatic Neoplasms (pathology), Prognosis, Rare Diseases (chemically induced), Rare Diseases (pathology).
- MESH :
- chemical , adverse effects : Deoxycytidine.
- chemical , analogs & derivatives : Deoxycytidine.
- chemically induced : Erysipeloid, Exanthema, Rare Diseases.
- drug therapy : Adenocarcinoma, Pancreatic Neoplasms.
- pathology : Adenocarcinoma, Erysipeloid, Exanthema, Pancreatic Neoplasms, Rare Diseases.
- Adult, Female, Humans, Prognosis.
Abstract
Some rare cases of erysipelas-like or pseudocellulitis have been reported in relation to gemcitabine. This rare adverse event is more frequent in the presence of edema. Here, we report a case of pseudocellulitis after adjuvant treatment for pancreatic cancer. Oncologists should be aware of this infrequent and non-well understood adverse event. They should be especially careful when administering gemcitabine in the presence of lymphedema.
DOI: 10.4103/0973-1482.148711
PubMed: 26881588
Links to Exploration step
pubmed:26881588Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Erysipeloid rash: A rare adverse event induced by gemcitabine.</title>
<author><name sortKey="Ruiz Casado, Ana" sort="Ruiz Casado, Ana" uniqKey="Ruiz Casado A" first="Ana" last="Ruiz-Casado">Ana Ruiz-Casado</name>
<affiliation><nlm:affiliation>Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gutierrez, David" sort="Gutierrez, David" uniqKey="Gutierrez D" first="David" last="Gutiérrez">David Gutiérrez</name>
</author>
<author><name sortKey="Juez, Ignacio" sort="Juez, Ignacio" uniqKey="Juez I" first="Ignacio" last="Juez">Ignacio Juez</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="????"><PubDate><MedlineDate>2015 Oct-Dec</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:26881588</idno>
<idno type="pmid">26881588</idno>
<idno type="doi">10.4103/0973-1482.148711</idno>
<idno type="wicri:Area/PubMed/Corpus">000999</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000999</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Erysipeloid rash: A rare adverse event induced by gemcitabine.</title>
<author><name sortKey="Ruiz Casado, Ana" sort="Ruiz Casado, Ana" uniqKey="Ruiz Casado A" first="Ana" last="Ruiz-Casado">Ana Ruiz-Casado</name>
<affiliation><nlm:affiliation>Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gutierrez, David" sort="Gutierrez, David" uniqKey="Gutierrez D" first="David" last="Gutiérrez">David Gutiérrez</name>
</author>
<author><name sortKey="Juez, Ignacio" sort="Juez, Ignacio" uniqKey="Juez I" first="Ignacio" last="Juez">Ignacio Juez</name>
</author>
</analytic>
<series><title level="j">Journal of cancer research and therapeutics</title>
<idno type="eISSN">1998-4138</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (drug therapy)</term>
<term>Adenocarcinoma (pathology)</term>
<term>Adult</term>
<term>Deoxycytidine (adverse effects)</term>
<term>Deoxycytidine (analogs & derivatives)</term>
<term>Erysipeloid (chemically induced)</term>
<term>Erysipeloid (pathology)</term>
<term>Exanthema (chemically induced)</term>
<term>Exanthema (pathology)</term>
<term>Female</term>
<term>Humans</term>
<term>Pancreatic Neoplasms (drug therapy)</term>
<term>Pancreatic Neoplasms (pathology)</term>
<term>Prognosis</term>
<term>Rare Diseases (chemically induced)</term>
<term>Rare Diseases (pathology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Deoxycytidine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Deoxycytidine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Erysipeloid</term>
<term>Exanthema</term>
<term>Rare Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Adenocarcinoma</term>
<term>Pancreatic Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Adenocarcinoma</term>
<term>Erysipeloid</term>
<term>Exanthema</term>
<term>Pancreatic Neoplasms</term>
<term>Rare Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>Prognosis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Some rare cases of erysipelas-like or pseudocellulitis have been reported in relation to gemcitabine. This rare adverse event is more frequent in the presence of edema. Here, we report a case of pseudocellulitis after adjuvant treatment for pancreatic cancer. Oncologists should be aware of this infrequent and non-well understood adverse event. They should be especially careful when administering gemcitabine in the presence of lymphedema.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26881588</PMID>
<DateCreated><Year>2016</Year>
<Month>02</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>11</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>12</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1998-4138</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>11</Volume>
<Issue>4</Issue>
<PubDate><MedlineDate>2015 Oct-Dec</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Journal of cancer research and therapeutics</Title>
<ISOAbbreviation>J Cancer Res Ther</ISOAbbreviation>
</Journal>
<ArticleTitle>Erysipeloid rash: A rare adverse event induced by gemcitabine.</ArticleTitle>
<Pagination><MedlinePgn>1024</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4103/0973-1482.148711</ELocationID>
<Abstract><AbstractText>Some rare cases of erysipelas-like or pseudocellulitis have been reported in relation to gemcitabine. This rare adverse event is more frequent in the presence of edema. Here, we report a case of pseudocellulitis after adjuvant treatment for pancreatic cancer. Oncologists should be aware of this infrequent and non-well understood adverse event. They should be especially careful when administering gemcitabine in the presence of lymphedema.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruiz-Casado</LastName>
<ForeName>Ana</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Medical Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gutiérrez</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Juez</LastName>
<ForeName>Ignacio</ForeName>
<Initials>I</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>India</Country>
<MedlineTA>J Cancer Res Ther</MedlineTA>
<NlmUniqueID>101249598</NlmUniqueID>
<ISSNLinking>1998-4138</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0W860991D6</RegistryNumber>
<NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>B76N6SBZ8R</RegistryNumber>
<NameOfSubstance UI="C056507">gemcitabine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003841" MajorTopicYN="N">Deoxycytidine</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004887" MajorTopicYN="N">Erysipeloid</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005076" MajorTopicYN="N">Exanthema</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D035583" MajorTopicYN="N">Rare Diseases</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>2</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>2</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>11</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26881588</ArticleId>
<ArticleId IdType="pii">JCanResTher_2015_11_4_1024_148711</ArticleId>
<ArticleId IdType="doi">10.4103/0973-1482.148711</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000999 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000999 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:26881588 |texte= Erysipeloid rash: A rare adverse event induced by gemcitabine. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26881588" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |